Press Releases

 
Press Releases
Date Title and Summary View
Jun 19, 2017 SALT LAKE CITY, June 19, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, to...
Jun 15, 2017 SALT LAKE CITY, June 15, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data from a meta-analysis of clinical studies and a registry demonstrating the ability of the Vectra® DA test to predict joint damage were presented at the European...
Jun 8, 2017 SALT LAKE CITY, June 08, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the Vectra® DA test will be presented at the European League Against Rheumatism (EULAR) meeting being held June 14-17, 2017, in Mad...
Jun 4, 2017 SALT LAKE CITY, June 04, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today...
Jun 2, 2017 SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that multiple new insurance plans have announced positive coverage policies for EndoPredict. Recently, Blue Shield of California, Humana, Inc., and multiple regiona...
Jun 2, 2017 SALT LAKE CITY, June 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced re...
May 31, 2017 SALT LAKE CITY, May 31, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that Mark C. Capone, president and CEO, is scheduled to present at the William Blair Growth Stock Conference at 12:40 p.m. CDT on June 14, 2017, at the Four Seasons Hotel in Chicag...
May 30, 2017 SALT LAKE CITY, May 30, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Goldman Sachs Global Healthcare Conference at 10:00 a.m. PDT on June 13, 2017, at the Terranea Resort i...
May 25, 2017 SALT LAKE CITY, May 25, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnost...
May 18, 2017 SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and perso...
Page:
1
... NextLast
= add release to Briefcase